LOS ANGELES, Feb. 3, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to BellRing Brands, Inc. ("BellRing " or the Company") (NYSE: BRBR) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BELLRING BRANDS, INC. (BRBR), CLICK HERE BEFORE MARCH 23, 2026 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. What Is The Lawsuit About? The complaint filed alleges that, ...

Core Viewpoint - The Law Offices of Frank R. Cruz is investigating Corcept Therapeutics Incorporated for potential violations of federal securities laws on behalf of investors who may have incurred losses [1] Group 1 - The investigation is focused on Corcept Therapeutics Incorporated (NASDAQ: CORT) and its compliance with federal securities regulations [1] - Investors who lost money on Corcept Therapeutics are encouraged to inquire about pursuing claims to recover their losses [1]

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Ultragenyx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class acti ...

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Mereo and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] During pre- ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving First Citizens BancShares and its officers or directors, following disappointing financial results and a significant stock price drop [1][3][4]. Financial Performance - On January 23, 2026, First Citizens reported its fourth-quarter financial results for 2025, revealing an efficiency ratio of 64.5%, which missed analyst expectations and worsened compared to the previous year [3]. - The company provided a weaker outlook, indicating expected deterioration in revenue and weak projections for net interest income in the upcoming year [3]. Stock Market Reaction - Following the announcement of the financial results, First Citizens' stock price fell by $186.97 per share, or 8.49%, closing at $2,016.56 per share on January 23, 2026 [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Capital One Financial Corporation and its officers or directors [1]. Financial Performance - On January 22, 2026, Capital One reported Q4 2025 earnings per share of $3.86, which fell short of analyst expectations of $4.14 [3]. - The company's efficiency ratio was reported at 60%, also missing analyst expectations [3]. - Following the earnings report, Capital One's stock price dropped by $17.77, or 7.56%, closing at $217.30 per share on January 23, 2026 [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving BlackRock TCP Capital Corp and its officers or directors [1] Group 1: Company Performance - On January 23, 2026, BlackRock TCP reported a 19% decline in the net asset value of its private corporate loans, attributed to a significant increase in nonperforming loans [3] - Following this announcement, BlackRock TCP's stock price decreased by $0.76 per share, representing a 12.97% drop, closing at $5.10 per share on January 26, 2026 [3] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of BlackRock TCP to discuss claims related to the company's potential involvement in securities fraud [1] - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Corcept Therapeutics and its officers or directors, following a significant stock price drop after the FDA's Complete Response Letter regarding a new drug application [1][3]. Group 1: Company Overview - Corcept Therapeutics Incorporated is a biopharmaceutical company focused on developing treatments for patients with conditions related to cortisol excess [3]. - The company’s stock price experienced a dramatic decline of $35.40 per share, or 50.42%, closing at $34.80 per share on December 31, 2025, after the FDA issued a Complete Response Letter regarding its drug relacorilant [3]. Group 2: Regulatory Developments - On December 31, 2025, the FDA issued a Complete Response Letter concerning Corcept's New Drug Application for relacorilant, indicating that while the pivotal GRACE trial met its primary endpoint, additional evidence of effectiveness was required for a favorable benefit-risk assessment [3]. Group 3: Legal Investigation - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is currently investigating claims on behalf of investors of Corcept, suggesting potential legal ramifications for the company and its leadership [1][4].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving REGENXBIO Inc. and its officers or directors [1] Group 1: Company Developments - On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its investigational gene therapy RGX-111 for treating MPS I due to a case of neoplasm in a participant [3] - The FDA also placed a clinical hold on RGX-121 for MPS II, citing similarities in products and shared risks between the studies [3] - Following the announcement, REGENXBIO's stock price dropped by $2.40 per share, or 17.9%, closing at $11.01 per share on the same day [3] Group 2: Legal and Investigative Actions - Pomerantz LLP is actively seeking investors of REGENXBIO to contact them regarding the investigation into potential securities fraud [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Zenas BioPharma, Inc. and its officers or directors, following disappointing results from a clinical trial that negatively impacted the company's stock price [1][3]. Group 1: Company Overview - Zenas BioPharma, Inc. is a publicly traded company on NASDAQ under the ticker ZBIO [1]. - The company recently announced results from the Phase 3 INDIGO trial of its drug obexelimab for Immunoglobulin G4-Related Disease (IgG4-RD) [3]. Group 2: Trial Results and Market Reaction - The trial results were characterized as "positive" by Zenas; however, analysts indicated that the drug's efficacy did not meet the necessary threshold for commercial viability [3]. - Following the announcement, Zenas's stock price dropped by $17.89 per share, or 51.86%, closing at $16.61 on January 5, 2026 [3]. - On a subsequent conference call, the CEO expressed disappointment regarding the drug's hazard ratio, which did not meet expectations, leading to an additional stock price decline of $1.41 per share, or 8.49%, closing at $15.20 on January 6, 2026 [4].